Insights into inflammasome regulation: cellular, molecular, and pathogenic control of inflammasome activation

1.

Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol. 2009;21(4):242–53. https://doi.org/10.1016/j.smim.2009.06.005.CrossRefPubMed

2.

Wu CH, Abd-El-Haliem A, Bozkurt TO, Belhaj K, Terauchi R, Vossen JH, et al. NLR network mediates immunity to diverse plant pathogens. Proc Natl Acad Sci U S A. 2017a;114(30):8113–8. https://doi.org/10.1073/pnas.1702041114.CrossRefPubMedPubMedCentral

3.

Zhong Y, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol. 2013a;4:333. https://doi.org/10.3389/fimmu.2013.00333.CrossRefPubMedPubMedCentral

4.

van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, et al. Inflammasome-dependent induction of adaptive NK cell memory. Immunity. 2016;44(6):1406–21. https://doi.org/10.1016/j.immuni.2016.05.008.CrossRefPubMed

5.

Bakele M, Joos M, Burdi S, Allgaier N, Poschel S, Fehrenbacher B, et al. Localization and functionality of the inflammasome in neutrophils. J Biol Chem. 2014;289(8):5320–9. https://doi.org/10.1074/jbc.M113.505636.CrossRefPubMedPubMedCentral

6.

Cornelius DC, Baik CH, Travis OK, White DL, Young CM, Austin Pierce W, et al. NLRP3 inflammasome activation in platelets in response to sepsis. Physiol Rep. 2019;7(9):e14073. https://doi.org/10.14814/phy2.14073.CrossRefPubMedPubMedCentral

7.

Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell. 2014;156(6):1193–206. https://doi.org/10.1016/j.cell.2014.02.008.CrossRefPubMedPubMedCentral

8.

Shen C, Lu A, Xie WJ, Ruan J, Negro R, Egelman EH, et al. Molecular mechanism for NLRP6 inflammasome assembly and activation. Proc Natl Acad Sci U S A. 2019;116(6):2052–7. https://doi.org/10.1073/pnas.1817221116.CrossRefPubMedPubMedCentral

9.

Radian AD, Khare S, Chu LH, Dorfleutner A, Stehlik C. ATP binding by NLRP7 is required for inflammasome activation in response to bacterial lipopeptides. Mol Immunol. 2015;67(2 Pt B):294–302. https://doi.org/10.1016/j.molimm.2015.06.013.CrossRefPubMedPubMedCentral

10.

Rossi MN, Pascarella A, Licursi V, Caiello I, Taranta A, Rega LR, et al. NLRP2 regulates proinflammatory and antiapoptotic responses in proximal tubular epithelial cells. Front Cell Dev Biol. 2019;7:252. https://doi.org/10.3389/fcell.2019.00252.CrossRefPubMedPubMedCentral

11.

von Moltke J, Ayres JS, Kofoed EM, Chavarria-Smith J, Vance RE. Recognition of bacteria by inflammasomes. Annu Rev Immunol. 2013;31:73–106. https://doi.org/10.1146/annurev-immunol-032712-095944.CrossRef

12.

Fernandes-Alnemri T, Wu J, Yu JW, Datta P, Miller B, Jankowski W, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14(9):1590–604. https://doi.org/10.1038/sj.cdd.4402194.CrossRefPubMed

13.

Nagar A, Rahman T, Harton JA. The ASC speck and NLRP3 inflammasome function are spatially and temporally distinct. Front Immunol. 2021;12:752482. https://doi.org/10.3389/fimmu.2021.752482.CrossRefPubMedPubMedCentral

14.

Jin T, Perry A, Smith P, Jiang J, Xiao TS. Structure of the absent in melanoma 2 (AIM2) pyrin domain provides insights into the mechanisms of AIM2 autoinhibition and inflammasome assembly. J Biol Chem. 2013;288(19):13225–35. https://doi.org/10.1074/jbc.M113.468033.CrossRefPubMedPubMedCentral

15.

Mathur A, Hayward JA, Man SM. Molecular mechanisms of inflammasome signaling. J Leukoc Biol. 2018;103(2):233–57. https://doi.org/10.1189/jlb.3MR0617-250R.CrossRefPubMed

16.

Shamaa OR, Mitra S, Gavrilin MA, Wewers MD. Monocyte caspase-1 is released in a stable, active high molecular weight complex distinct from the unstable cell lysate-activated caspase-1. PLoS One. 2015;10(11):e0142203. https://doi.org/10.1371/journal.pone.0142203.CrossRefPubMedPubMedCentral

17.

Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010a;11(12):1136–42. https://doi.org/10.1038/ni.1960.CrossRefPubMedPubMedCentral

18.

Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis. 2012;3:e338. https://doi.org/10.1038/cddis.2012.86.CrossRefPubMedPubMedCentral

19.

Ruhl S, Shkarina K, Demarco B, Heilig R, Santos JC, Broz P. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science. 2018;362(6417):956–60. https://doi.org/10.1126/science.aar7607.CrossRefPubMed

20.

Carty M, Kearney J, Shanahan KA, Hams E, Sugisawa R, Connolly D, et al. Cell survival and cytokine release after inflammasome activation is regulated by the Toll-IL-1R protein SARM. Immunity. 2019;50(6):1412–24 e6. https://doi.org/10.1016/j.immuni.2019.04.005.CrossRefPubMed

21.

Kayagaki N, Kornfeld OS, Lee BL, Stowe IB, O’Rourke K, Li Q, et al. NINJ1 mediates plasma membrane rupture during lytic cell death. Nature. 2021;591(7848):131–6. https://doi.org/10.1038/s41586-021-03218-7.CrossRefPubMed

22.

Chen M, Xing Y, Lu A, Fang W, Sun B, Chen C, et al. Internalized Cryptococcus neoformans Activates the canonical caspase-1 and the noncanonical caspase-8 inflammasomes. J Immunol. 2015;195(10):4962–72. https://doi.org/10.4049/jimmunol.1500865.CrossRefPubMed

23.

Ramirez MLG, Poreba M, Snipas SJ, Groborz K, Drag M, Salvesen GS. Extensive peptide and natural protein substrate screens reveal that mouse caspase-11 has much narrower substrate specificity than caspase-1. J Biol Chem. 2018;293(18):7058–67. https://doi.org/10.1074/jbc.RA117.001329.CrossRefPubMedPubMedCentral

24.

Diamond CE, Khameneh HJ, Brough D, Mortellaro A. Novel perspectives on non-canonical inflammasome activation. Immunotargets Ther. 2015;4:131–41. https://doi.org/10.2147/ITT.S57976.CrossRefPubMedPubMedCentral

25.

Yang J, Zhao Y, Shao F. Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity. Curr Opin Immunol. 2015;32:78–83. https://doi.org/10.1016/j.coi.2015.01.007.CrossRefPubMed

26.

Chen R, Zeng L, Zhu S, Liu J, Zeh HJ, Kroemer G, et al. cAMP metabolism controls caspase-11 inflammasome activation and pyroptosis in sepsis. Sci Adv. 2019;5(5):eaav5562. https://doi.org/10.1126/sciadv.aav5562.CrossRefPubMedPubMedCentral

27.

Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535(7610):153–8. https://doi.org/10.1038/nature18629.CrossRefPubMedPubMedCentral

28.

Hatscher L, Amon L, Heger L, Dudziak D. Inflammasomes in dendritic cells: Friend or foe? Immunol Lett. 2021a;234:16–32. https://doi.org/10.1016/j.imlet.2021.04.002.CrossRefPubMed

29.

Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020;6:36. https://doi.org/10.1038/s41421-020-0167-x.CrossRefPubMedPubMedCentral

30.

Man SM, Hopkins LJ, Nugent E, Cox S, Gluck IM, Tourlomousis P, et al. Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex. Proc Natl Acad Sci U S A. 2014;111(20):7403–8. https://doi.org/10.1073/pnas.1402911111.CrossRefPubMedPubMedCentral

31.

Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103(26):9982–7. https://doi.org/10.1073/pnas.0602081103.CrossRefPubMedPubMedCentral

32.

Papin S, Cuenin S, Agostini L, Martinon F, Werner S, Beer HD, et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 2007;14(8):1457–66. https://doi.org/10.1038/sj.cdd.4402142.CrossRefPubMed

33.

Lu WL, Zhang L, Song DZ, Yi XW, Xu WZ, Ye L, et al. NLRP6 suppresses the inflammatory response of human periodontal ligament cells by inhibiting NF-kappaB and ERK signal pathways. Int Endod J. 2019;52(7):999–1009. https://doi.org/10.1111/iej.13091.CrossRefPubMed

34.

Wang Q, Liu F, Zhang M, Zhou P, Xu C, Li Y, et al. NLRP12 promotes mouse neutrophil differentiation through regulation of non-canonical NF-kappaB and MAPK(ERK1/2) signaling. Int J Biol Sci. 2018;14(2):147–55. https://doi.org/10.7150/ijbs.23231.CrossRefPubMedPubMedCentral

35.

Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity. 2012;36(5):742–54. https://doi.org/10.1016/j.immuni.2012.03.012.CrossRefPubMedPubMedCentral

36.

Davis BK, Roberts RA, Huang MT, Willingham SB, Conti BJ, Brickey WJ, et al. Cutting edge: NLRC5-dependent activation of the inflammasome. J Immunol. 2011;186(3):1333–7. https://doi.org/10.4049/jimmunol.1003111.CrossRefPubMed

37.

Wang M, Wang L, Fang L, Li S, Liu R. NLRC5 negatively regulates LTA-induced inflammation via TLR2/NF-kappaB and participates in TLR2-mediated allergic airway inflammation. J Cell Physiol. 2019a;234(11):19990–20001. https://doi.org/10.1002/jcp.28596.CrossRefPubMed

38.

Messaed C, Akoury E, Djuric U, Zeng J, Saleh M, Gilbert L, et al. NLRP7, a nucleotide oligomerization domain-like receptor protein, is required for normal cytokine secretion and co-localizes with Golgi and the microtubule-organizing center. J Biol Chem. 2011;286(50):43313–23. https://doi.org/10.1074/jbc.M111.306191.CrossRefPubMedPubMedCentral

39.

Kinoshita T, Wang Y, Hasegawa M, Imamura R, Suda T. PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1beta secretion. J Biol Chem. 2005;280(23):21720–5. https://doi.org/10.1074/jbc.M410057200.CrossRefPubMed

40.

Gultekin Y, Eren E, Ozoren N. Overexpressed NLRC3 acts as an anti-inflammatory cytosolic protein. J Innate Immun. 2015;7(1):25–36. https://doi.org/10.1159/000363602.CrossRefPubMed

41.

Abe T, Shapira SD. Negative regulation of cytosolic sensing of DNA. Int Rev Cell Mol Biol. 2019a;344:91–115. https://doi.org/10.1016/bs.ircmb.2018.09.002.CrossRefPubMed

42.

Yang Y, Lang X, Sun S, Gao C, Hu J, Ding S, et al. NLRP2 negatively regulates antiviral immunity by interacting with TBK1. Eur J Immunol. 2018;48(11):1817–25. https://doi.org/10.1002/eji.201847589.CrossRefPubMed

43.

Tilburgs T, Meissner TB, Ferreira LMR, Mulder A, Musunuru K, Ye J, et al. NLRP2 is a suppressor of NF-kB signaling and HLA-C expression in human trophoblastsdagger,double dagger. Biol Reprod. 2017;96(4):831–42. https://doi.org/10.1093/biolre/iox009.CrossRefPubMedPubMedCentral

44.

Wu C, Su Z, Lin M, Ou J, Zhao W, Cui J, et al. NLRP11 attenuates Toll-like receptor signalling by targeting TRAF6 for degradation via the ubiquitin ligase RNF19A. Nat Commun. 2017b;8(1):1977. https://doi.org/10.1038/s41467-017-02073-3.CrossRefPubMedPubMedCentral

45.

Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol. 2010;11(1):63–9. https://doi.org/10.1038/ni.1824.CrossRefPubMed

46.

Neerincx A, Lautz K, Menning M, Kremmer E, Zigrino P, Hosel M, et al. A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses. J Biol Chem. 2010;285(34):26223–32. https://doi.org/10.1074/jbc.M110.109736.CrossRefPubMedPubMedCentral

47.

Atianand MK, Fuchs T, Harton JA. Recent evolution of the NF-kappaB and inflammasome regulating protein POP2 in primates. BMC Evol Biol. 2011;11:56. https://doi.org/10.1186/1471-2148-11-56.CrossRefPubMedPubMedCentral

48.

Stehlik C, Fiorentino L, Dorfleutner A, Bruey JM, Ariza EM, Sagara J, et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappaB activation pathways. J Exp Med. 2002;196(12):1605–15. https://doi.org/10.1084/jem.20021552.CrossRefPubMedPubMedCentral

49.

Fiorentino L, Stehlik C, Oliveira V, Ariza ME, Godzik A, Reed JC. A novel PAAD-containing protein that modulates NF-kappa B induction by cytokines tumor necrosis factor-alpha and interleukin-1beta. J Biol Chem. 2002;277(38):35333–40. https://doi.org/10.1074/jbc.M200446200.CrossRefPubMed

50.

Bedoya F, Sandler LL, Harton JA. Pyrin-only protein 2 modulates NF-kappaB and disrupts ASC:CLR interactions. J Immunol. 2007;178(6):3837–45. https://doi.org/10.4049/jimmunol.178.6.3837.CrossRefPubMed

51.

Le HT, Harton JA. Pyrin- and CARD-only proteins as regulators of NLR functions. Front Immunol. 2013;4:275. https://doi.org/10.3389/fimmu.2013.00275.CrossRefPubMedPubMedCentral

52.

He Y, Zeng MY, Yang D, Motro B, Nunez G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530(7590):354–7. https://doi.org/10.1038/nature16959.CrossRefPubMedPubMedCentral

53.

Xu Z, Chen ZM, Wu X, Zhang L, Cao Y, Zhou P. Distinct molecular mechanisms underlying potassium efflux for NLRP3 inflammasome activation. Front Immunol. 2020;11:609441. https://doi.org/10.3389/fimmu.2020.609441.CrossRefPubMedPubMedCentral

54.

Jager E, Murthy S, Schmidt C, Hahn M, Strobel S, Peters A, et al. Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun. 2020;11(1):4243. https://doi.org/10.1038/s41467-020-17749-6.CrossRefPubMedPubMedCentral

55.

Gong T, Yang Y, Jin T, Jiang W, Zhou R. Orchestration of NLRP3 inflammasome activation by ion fluxes. Trends Immunol. 2018;39(5):393–406. https://doi.org/10.1016/j.it.2018.01.009.CrossRefPubMed

56.

Hafner-Bratkovic I, Pelegrin P. Ion homeostasis and ion channels in NLRP3 inflammasome activation and regulation. Curr Opin Immunol. 2018;52:8–17. https://doi.org/10.1016/j.coi.2018.03.010.CrossRefPubMed

57.

Li C, Chen M, He X, Ouyang D. A mini-review on ion fluxes that regulate NLRP3 inflammasome activation. Acta Biochim Biophys Sin Shanghai. 2021;53(2):131–9. https://doi.org/10.1093/abbs/gmaa155.CrossRefPubMed

58.

Naseer N, Bauer R, Zhang J, Brodsky IE, Rauch I, Shin SJb. Salmonella Typhimurium induces NAIP/NLRC4-and NLRP3/ASC-independent, caspase-1/4-dependent inflammasome activation in human intestinal epithelial cells. bioRxiv 2021;12.09.472040. https://doi.org/10.1101/2021.12.09.472040

59.

Krause K, Amer AO. Caspase exploitation by Legionella pneumophila. Front Microbiol. 2016;7:515. https://doi.org/10.3389/fmicb.2016.00515.CrossRefPubMedPubMedCentral

60.

Theisen E, Sauer JD. Listeria monocytogenes and the inflammasome: from cytosolic bacteriolysis to tumor immunotherapy. Curr Top Microbiol Immunol. 2016;397:133–60. https://doi.org/10.1007/978-3-319-41171-2_7.CrossRefPubMedPubMedCentral

61.

Wellington M, Koselny K, Sutterwala FS, Krysan DJ. Candida albicans triggers NLRP3-mediated pyroptosis in macrophages. Eukaryot Cell. 2014;13(2):329–40. https://doi.org/10.1128/EC.00336-13.CrossRefPubMedPubMedCentral

62.

Fang R, Tsuchiya K, Kawamura I, Shen Y, Hara H, Sakai S, et al. Critical roles of ASC inflammasomes in caspase-1 activation and host innate resistance to Streptococcus pneumoniae infection. J Immunol. 2011;187(9):4890–9. https://doi.org/10.4049/jimmunol.1100381.CrossRefPubMed

63.

Moretti J, Blander JM. Insights into phagocytosis-coupled activation of pattern recognition receptors and inflammasomes. Curr Opin Immunol. 2014;26:100–10. https://doi.org/10.1016/j.coi.2013.11.003.CrossRefPubMed

64.

Asgari E, Le Friec G, Yamamoto H, Perucha E, Sacks SS, Kohl J, et al. C3a modulates IL-1beta secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 2013;122(20):3473–81. https://doi.org/10.1182/blood-2013-05-502229.CrossRefPubMed

65.

Suresh R, Chandrasekaran P, Sutterwala FS, Mosser DM. Complement-mediated ‘bystander’ damage initiates host NLRP3 inflammasome activation. J Cell Sci. 2016;129(9):1928–39. https://doi.org/10.1242/jcs.179291.CrossRefPubMedPubMedCentral

66.

Sokolovska A, Becker CE, Ip WK, Rathinam VA, Brudner M, Paquette N, et al. Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function. Nat Immunol. 2013;14(6):543–53. https://doi.org/10.1038/ni.2595.CrossRefPubMedPubMedCentral

67.

Petrovski G, Zahuczky G, Majai G, Fesus L. Phagocytosis of cells dying through autophagy evokes a pro-inflammatory response in macrophages. Autophagy. 2007;3(5):509–11. https://doi.org/10.4161/auto.4731.CrossRefPubMed

68.

Petrovski G, Ayna G, Majai G, Hodrea J, Benko S, Madi A, et al. Phagocytosis of cells dying through autophagy induces inflammasome activation and IL-1beta release in human macrophages. Autophagy. 2011;7(3):321–30. https://doi.org/10.4161/auto.7.3.14583.CrossRefPubMed

69.

Wu MY, Lu JH. Autophagy and Macrophage functions: inflammatory response and phagocytosis. Cells. 2019;9(1). https://doi.org/10.3390/cells9010070.

70.

Merkley SD, Chock CJ, Yang XO, Harris J, Castillo EF. Modulating T cell responses via autophagy: the intrinsic influence controlling the function of both antigen-presenting cells and T cells. Front Immunol. 2018;9:2914. https://doi.org/10.3389/fimmu.2018.02914.CrossRefPubMedPubMedCentral

71.

Shi CS, Kehrl JH. Cytochrome c negatively regulates NLRP3 inflammasomes. PLoS One. 2016;11(12):e0167636. https://doi.org/10.1371/journal.pone.0167636.CrossRefPubMedPubMedCentral

72.

Conos SA, Chen KW, De Nardo D, Hara H, Whitehead L, Nunez G, et al. Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc Natl Acad Sci U S A. 2017;114(6):E961–E9. https://doi.org/10.1073/pnas.1613305114.CrossRefPubMedPubMedCentral

73.

Gutierrez KD, Davis MA, Daniels BP, Olsen TM, Ralli-Jain P, Tait SW, et al. MLKL Activation triggers NLRP3-mediated processing and release of IL-1beta independently of gasdermin-D. J Immunol. 2017;198(5):2156–64. https://doi.org/10.4049/jimmunol.1601757.CrossRefPubMed

74.

Couturier J, Stancu IC, Schakman O, Pierrot N, Huaux F, Kienlen-Campard P, et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease. J Neuroinflammation. 2016;13:20. https://doi.org/10.1186/s12974-016-0477-y.CrossRefPubMedPubMedCentral

75.

Pedicino D, Giglio AF, Ruggio A, Massaro G, D’Aiello A, Trotta F, et al. Inflammasome, T Lymphocytes and innate-adaptive immunity crosstalk: role in cardiovascular disease and therapeutic perspectives. Thromb Haemost. 2018;118(8):1352–69. https://doi.org/10.1055/s-0038-1666860.CrossRefPubMed

76.

Tsuchiya K. Inflammasome-associated cell death: Pyroptosis, apoptosis, and physiological implications. Microbiol Immunol. 2020;64(4):252–69. https://doi.org/10.1111/1348-0421.12771.CrossRefPubMed

77.

Tucey TM, Verma J, Olivier FAB, Lo TL, Robertson AAB, Naderer T, et al. Metabolic competition between host and pathogen dictates inflammasome responses to fungal infection. PLoS Pathog. 2020;16(8):e1008695. https://doi.org/10.1371/journal.ppat.1008695.CrossRefPubMedPubMedCentral

78.

Wolf AJ, Reyes CN, Liang W, Becker C, Shimada K, Wheeler ML, et al. Hexokinase is an innate immune receptor for the detection of bacterial peptidoglycan. Cell. 2016;166(3):624–36. https://doi.org/10.1016/j.cell.2016.05.076.CrossRefPubMedPubMedCentral

79.

Wynosky-Dolfi MA, Snyder AG, Philip NH, Doonan PJ, Poffenberger MC, Avizonis D, et al. Oxidative metabolism enables Salmonella evasion of the NLRP3 inflammasome. J Exp Med. 2014;211(4):653–68. https://doi.org/10.1084/jem.20130627.CrossRefPubMedPubMedCentral

80.

Yang Q, Liu R, Yu Q, Bi Y, Liu G. Metabolic regulation of inflammasomes in inflammation. Immunology. 2019a;157(2):95–109. https://doi.org/10.1111/imm.13056.CrossRefPubMedPubMedCentral

81.

Zhang YZ, Sui XL, Xu YP, Gu FJ, Zhang AS, Chen JH. NLRP3 inflammasome and lipid metabolism analysis based on UPLC-Q-TOF-MS in gouty nephropathy. Int J Mol Med. 2019;44(1):172–84. https://doi.org/10.3892/ijmm.2019.4176.CrossRefPubMedPubMedCentral

82.

Papa S, Choy PM, Bubici C. The ERK and JNK pathways in the regulation of metabolic reprogramming. Oncogene. 2019;38(13):2223–40. https://doi.org/10.1038/s41388-018-0582-8.CrossRefPubMed

83.

Balic A, Vlasic D, Zuzul K, Marinovic B, Bukvic MZ. Omega-3 versus omega-6 polyunsaturated fatty acids in the prevention and treatment of inflammatory skin diseases. Int J Mol Sci. 2020;21(3). https://doi.org/10.3390/ijms21030741.

84.

Dempsey LA. Bile acids block NLRP3. Nat Immunol. 2016;17(11):1243. https://doi.org/10.1038/ni.3597.CrossRefPubMed

85.

Dang EV, McDonald JG, Russell DW, Cyster JG. Oxysterol restraint of cholesterol synthesis prevents AIM2 inflammasome activation. Cell. 2017;171(5):1057–71 e11. https://doi.org/10.1016/j.cell.2017.09.029.CrossRefPubMedPubMedCentral

86.

Jorgensen I, Lopez JP, Laufer SA, Miao EA. IL-1beta, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptosis. Eur J Immunol. 2016;46(12):2761–6. https://doi.org/10.1002/eji.201646647.CrossRefPubMedPubMedCentral

87.

Maier NK, Leppla SH, Moayeri M. The cyclopentenone prostaglandin 15d-PGJ2 inhibits the NLRP1 and NLRP3 inflammasomes. J Immunol. 2015;194(6):2776–85. https://doi.org/10.4049/jimmunol.1401611.CrossRefPubMed

88.

Kunz TC, Kozjak-Pavlovic V. Diverse facets of sphingolipid involvement in bacterial infections. Front Cell Dev Biol. 2019;7:203. https://doi.org/10.3389/fcell.2019.00203.CrossRefPubMedPubMedCentral

89.

Luheshi NM, Giles JA, Lopez-Castejon G, Brough D. Sphingosine regulates the NLRP3-inflammasome and IL-1beta release from macrophages. Eur J Immunol. 2012;42(3):716–25. https://doi.org/10.1002/eji.201142079.CrossRefPubMed

90.

Anand PK. Lipids, inflammasomes, metabolism, and disease. Immunol Rev. 2020;297(1):108–22. https://doi.org/10.1111/imr.12891.CrossRefPubMed

91.

Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012;491(7423):259–63. https://doi.org/10.1038/nature11535.CrossRefPubMedPubMedCentral

92.

Wlodarska M, Thaiss CA, Nowarski R, Henao-Mejia J, Zhang JP, Brown EM, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell. 2014;156(5):1045–59. https://doi.org/10.1016/j.cell.2014.01.026.CrossRefPubMedPubMedCentral

93.

Levy M, Thaiss CA, Zeevi D, Dohnalova L, Zilberman-Schapira G, Mahdi JA, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163(6):1428–43. https://doi.org/10.1016/j.cell.2015.10.048.CrossRefPubMedPubMedCentral

94.

Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol. 2012;189(8):3795–9. https://doi.org/10.4049/jimmunol.1200312.CrossRefPubMed

95.

Dang CP, Leelahavanichkul A. Over-expression of miR-223 induces M2 macrophage through glycolysis alteration and attenuates LPS-induced sepsis mouse model, the cell-based therapy in sepsis. PLoS One. 2020;15(7):e0236038. https://doi.org/10.1371/journal.pone.0236038.CrossRefPubMedPubMedCentral

96.

Zheng CG, Chen BY, Sun RH, Mou XZ, Han F, Li Q, et al. miR-133b downregulation reduces vulnerable plaque formation in mice with AS through inhibiting macrophage immune responses. Mol Ther Nucleic Acids. 2019;16:745–57. https://doi.org/10.1016/j.omtn.2019.04.024.CrossRefPubMedPubMedCentral

97.

Miranda K, Yang X, Bam M, Murphy EA, Nagarkatti PS, Nagarkatti M. MicroRNA-30 modulates metabolic inflammation by regulating Notch signaling in adipose tissue macrophages. Int J Obes. 2018;42(6):1140–50. https://doi.org/10.1038/s41366-018-0114-1.CrossRef

98.

Lou J, Wang Y, Zhang Z, Qiu W. MiR-20b inhibits mycobacterium tuberculosis induced inflammation in the lung of mice through targeting NLRP3. Exp Cell Res. 2017;358(2):120–8. https://doi.org/10.1016/j.yexcr.2017.06.007.CrossRefPubMed

99.

Curtale G, Rubino M, Locati M. MicroRNAs as molecular switches in macrophage activation. Front Immunol. 2019;10:799. https://doi.org/10.3389/fimmu.2019.00799.CrossRefPubMedPubMedCentral

100.

Kan OK, Matsumoto K, Inoue H, Fukuyama S, Asai Y, Watanabe W, et al. Corticosteroids plus long-acting beta2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium. Int Arch Allergy Immunol. 2013;160(1):27–36. https://doi.org/10.1159/000338430.CrossRef

101.

Boxberger N, Hecker M, Zettl UK. Dysregulation of inflammasome priming and activation by microRNAs in human immune-mediated diseases. J Immunol. 2019;202(8):2177–87. https://doi.org/10.4049/jimmunol.1801416.CrossRefPubMed

102.

Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. 2012;13(4):333–42. https://doi.org/10.1038/ni.2237.CrossRefPubMedPubMedCentral

103.

Felley LE, Sharma A, Theisen E, Romero-Masters JC, Sauer JD, Gumperz JE. Human invariant NKT cells induce IL-1beta secretion by peripheral blood monocytes via a P2X7-independent pathway. J Immunol. 2016;197(6):2455–64. https://doi.org/10.4049/jimmunol.1600790.CrossRefPubMed

104.

Suarez-Alvarez B, Rodriguez RM, Schlangen K, Raneros AB, Marquez-Kisinousky L, Fernandez AF, et al. Phenotypic characteristics of aged CD4(+) CD28(null) T lymphocytes are determined by changes in the whole-genome DNA methylation pattern. Aging Cell. 2017;16(2):293–303. https://doi.org/10.1111/acel.12552.CrossRefPubMed

105.

Chandel HS, Pandey SP, Roy S, Doyen N, Saha B. TLR-CD40 cross-talk in anti-leishmanial immune response. Front Immunol. 2014;5:220. https://doi.org/10.3389/fimmu.2014.00220.CrossRefPubMedPubMedCentral

106.

Gaikwad S, Patel D, Agrawal-Rajput R. CD40 negatively regulates ATP-TLR4-activated inflammasome in microglia. Cell Mol Neurobiol. 2017;37(2):351–9. https://doi.org/10.1007/s10571-016-0358-z.CrossRefPubMed

107.

Li Y, Yang X, He Y, Wang W, Zhang J, Zhang W, et al. Negative regulation of NLRP3 inflammasome by SIRT1 in vascular endothelial cells. Immunobiology. 2017;222(3):552–61. https://doi.org/10.1016/j.imbio.2016.11.002.CrossRefPubMed

108.

Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014;1319:82–95. https://doi.org/10.1111/nyas.12458.CrossRefPubMedPubMedCentral

109.

Theivanthiran B, Evans KS, DeVito NC, Plebanek M, Sturdivant M, Wachsmuth LP, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020a;130(5):2570–86. https://doi.org/10.1172/JCI133055.CrossRefPubMedPubMedCentral

110.

Lan P, Fan Y, Zhao Y, Lou X, Monsour HP, Zhang X, et al. TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury. J Clin Invest. 2017;127(6):2222–34. https://doi.org/10.1172/JCI91075.CrossRefPubMedPubMedCentral

111.

Huang JH, Chiang BL. Regulatory T cells induced by B cells suppress NLRP3 inflammasome activation and alleviate monosodium urate-induced gouty inflammation. iScience. 2021;24(2):102103. https://doi.org/10.1016/j.isci.2021.102103.CrossRefPubMedPubMedCentral

112.

Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol. 2013;14(1):52–60. https://doi.org/10.1038/ni.2474.CrossRefPubMed

113.

Kopitar-Jerala N. The role of interferons in inflammation and inflammasome activation. Front Immunol. 2017;8:873. https://doi.org/10.3389/fimmu.2017.00873.CrossRefPubMedPubMedCentral

114.

Hwang I, Yang J, Hong S, Ju Lee E, Lee SH, Fernandes-Alnemri T, et al. Non-transcriptional regulation of NLRP3 inflammasome signaling by IL-4. Immunol Cell Biol. 2015;93(6):591–9. https://doi.org/10.1038/icb.2014.125.CrossRefPubMedPubMedCentral

115.

Bryant AH, Spencer-Harty S, Owens SE, Jones RH, Thornton CA. Interleukin 4 and interleukin 13 downregulate the lipopolysaccharide-mediated inflammatory response by human gestation-associated tissues. Biol Reprod. 2017;96(3):576–86. https://doi.org/10.1095/biolreprod.116.145680.CrossRefPubMed

116.

Sun Y, Ma J, Li D, Li P, Zhou X, Li Y, et al. Interleukin-10 inhibits interleukin-1beta production and inflammasome activation of microglia in epileptic seizures. J Neuroinflammation. 2019;16(1):66. https://doi.org/10.1186/s12974-019-1452-1.CrossRefPubMedPubMedCentral

117.

Wang S, Fan J, Mei X, Luan J, Li Y, Zhang X, et al. Interleukin-22 attenuated renal tubular injury in aristolochic acid nephropathy via suppressing activation of NLRP3 inflammasome. Front Immunol. 2019b;10:2277. https://doi.org/10.3389/fimmu.2019.02277.CrossRefPubMedPubMedCentral

118.

Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Wisnewsky J, et al. T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes. 2014;63(6):1966–77. https://doi.org/10.2337/db13-1511.CrossRefPubMed

119.

Borghi M, De Luca A, Puccetti M, Jaeger M, Mencacci A, Oikonomou V, et al. Pathogenic NLRP3 inflammasome activity during Candida infection is negatively regulated by IL-22 via activation of NLRC4 and IL-1Ra. Cell Host Microbe. 2015;18(2):198–209. https://doi.org/10.1016/j.chom.2015.07.004.CrossRefPubMed

120.

Le Jan S, Muller C, Plee J, Durlach A, Bernard P, Antonicelli F. IL-23/IL-17 axis activates IL-1beta-associated inflammasome in macrophages and generates an auto-inflammatory response in a subgroup of patients with bullous pemphigoid. Front Immunol. 2019;10:1972. https://doi.org/10.3389/fimmu.2019.01972.CrossRefPubMedPubMedCentral

121.

Jain A, Irizarry-Caro RA, McDaniel MM, Chawla AS, Carroll KR, Overcast GR, et al. T cells instruct myeloid cells to produce inflammasome-independent IL-1beta and cause autoimmunity. Nat Immunol. 2020;21(1):65–74. https://doi.org/10.1038/s41590-019-0559-y.CrossRefPubMed

122.

Sharma D, Malik A, Guy C, Vogel P, Kanneganti TD. TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy. J Clin Invest. 2019;129(1):150–62. https://doi.org/10.1172/JCI121372.CrossRefPubMed

123.

McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD, Pena CA, et al. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest. 2017;127(12):4488–97. https://doi.org/10.1172/JCI90699.CrossRefPubMedPubMedCentral

124.

Boro M, Balaji KN. CXCL1 and CXCL2 Regulate NLRP3 inflammasome activation via G-protein-coupled receptor CXCR2. J Immunol. 2017;199(5):1660–71. https://doi.org/10.4049/jimmunol.1700129.CrossRefPubMed

125.

Masumoto J, Yang K, Varambally S, Hasegawa M, Tomlins SA, Qiu S, et al. Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. J Exp Med. 2006;203(1):203–13. https://doi.org/10.1084/jem.20051229.CrossRefPubMedPubMedCentral

126.

Inoue M, Williams KL, Gunn MD, Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2012;109(26):10480–5. https://doi.org/10.1073/pnas.1201836109.CrossRefPubMedPubMedCentral

127.

Amati AL, Zakrzewicz A, Siebers R, Wilker S, Heldmann S, Zakrzewicz D, et al. Chemokines (CCL3, CCL4, and CCL5) inhibit ATP-induced release of IL-1beta by monocytic cells. Mediat Inflamm. 2017;2017:1434872. https://doi.org/10.1155/2017/1434872.CrossRef

128.

Deng W, Bai Y, Deng F, Pan Y, Mei S, Zheng Z, et al. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature. 2022. https://doi.org/10.1038/s41586-021-04384-4.

129.

Foschi C, Bortolotti M, Marziali G, Polito L, Marangoni A, Bolognesi A. Survival and death of intestinal cells infected by Chlamydia trachomatis. PLoS One. 2019;14(4):e0215956. https://doi.org/10.1371/journal.pone.0215956.CrossRefPubMedPubMedCentral

130.

Gatto M, Borim PA, Wolf IR, Fukuta da Cruz T, Ferreira Mota GA, Marques Braz AM, et al. Transcriptional analysis of THP-1 cells infected with Leishmania infantum indicates no activation of the inflammasome platform. PLoS Negl Trop Dis. 2020;14(1):e0007949. https://doi.org/10.1371/journal.pntd.0007949.CrossRefPubMedPubMedCentral

131.

Tucey TM, Verma-Gaur J, Nguyen J, Hewitt VL, Lo TL, Shingu-Vazquez M, et al. The endoplasmic reticulum-mitochondrion tether ERMES orchestrates fungal immune evasion, illuminating inflammasome responses to hyphal signals. mSphere. 2016;1(3). https://doi.org/10.1128/mSphere.00074-16.

132.

Komatsu T, Tanaka Y, Kitagawa Y, Koide N, Naiki Y, Morita N, et al. Sendai virus V protein inhibits the secretion of interleukin-1beta by preventing NLRP3 inflammasome assembly. J Virol. 2018;92(19). https://doi.org/10.1128/JVI.00842-18.

133.

Gim E, Shim DW, Hwang I, Shin OS, Yu JW. Zika virus impairs host NLRP3-mediated inflammasome activation in an NS3-dependent manner. Immune Netw. 2019;19(6):e40. https://doi.org/10.4110/in.2019.19.e40.CrossRefPubMedPubMedCentral

134.

Zheng Y, Liu Q, Wu Y, Ma L, Zhang Z, Liu T, et al. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspase-1 axis. EMBO J. 2018;37(18). https://doi.org/10.15252/embj.201899347.

135.

Evavold CL, Kagan JC. How inflammasomes inform adaptive immunity. J Mol Biol. 2018;430(2):217–37. https://doi.org/10.1016/j.jmb.2017.09.019.CrossRefPubMed

136.

Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, et al. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother. 2010;33(3):287–96. https://doi.org/10.1097/CJI.0b013e3181c80ffa.CrossRefPubMed

137.

Cai Y, Xue F, Qin H, Chen X, Liu N, Fleming C, et al. Differential roles of the mTOR-STAT3 signaling in dermal gammadelta T cell effector function in skin inflammation. Cell Rep. 2019;27(10):3034–48 e5. https://doi.org/10.1016/j.celrep.2019.05.019.CrossRefPubMedPubMedCentral

138.

Hatscher L, Lehmann CHK, Purbojo A, Onderka C, Liang C, Hartmann A, et al. Select hyperactivating NLRP3 ligands enhance the TH1- and TH17-inducing potential of human type 2 conventional dendritic cells. Sci Signal. 2021b;14(680). https://doi.org/10.1126/scisignal.abe1757.

139.

Tourlomousis P, Wright JA, Bittante AS, Hopkins LJ, Webster SJ, Bryant OJ, et al. Modifying bacterial flagellin to evade Nod-like receptor CARD 4 recognition enhances protective immunity against Salmonella. Nat Microbiol. 2020;5(12):1588–97. https://doi.org/10.1038/s41564-020-00801-y.CrossRefPubMedPubMedCentral

140.

McDaniel MM, Kottyan LC, Singh H, Pasare C. Suppression of inflammasome activation by IRF8 and IRF4 in cDCs is critical for T cell priming. Cell Rep. 2020;31(5):107604. https://doi.org/10.1016/j.celrep.2020.107604.CrossRefPubMedPubMedCentral

141.

Budai MM, Tozser J, Benko S. Different dynamics of NLRP3 inflammasome-mediated IL1beta production in GM-CSF- and M-CSF-differentiated human macrophages. J Leukoc Biol. 2017;101(6):1335–47. https://doi.org/10.1189/jlb.3A0716-300RR.CrossRefPubMed

142.

Pelegrin P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J. 2009;28(14):2114–27. https://doi.org/10.1038/emboj.2009.163.CrossRefPubMedPubMedCentral

143.

Awad F, Assrawi E, Jumeau C, Georgin-Lavialle S, Cobret L, Duquesnoy P, et al. Impact of human monocyte and macrophage polarization on NLR expression and NLRP3 inflammasome activation. PLoS One. 2017;12(4):e0175336. https://doi.org/10.1371/journal.pone.0175336.CrossRefPubMedPubMedCentral

144.

Simmons DP, Nguyen H, Gomez-Rivas E, Jeong Y, Chen AF, Lange JK et al. SLAMF7 engagement super-activates macrophages in acute and chronic inflammation. 2020.

145.

Lopez-Castejon G, Baroja-Mazo A, Pelegrin P. Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules. Cell Mol Life Sci. 2011;68(18):3095–107. https://doi.org/10.1007/s00018-010-0609-y.CrossRefPubMed

146.

Daley D, Mani VR, Mohan N, Akkad N, Pandian G, Savadkar S, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med. 2017;214(6):1711–24. https://doi.org/10.1084/jem.20161707.CrossRefPubMedPubMedCentral

147.

Suzuki K, Meguro K, Nakagomi D, Nakajima H. Roles of alternatively activated M2 macrophages in allergic contact dermatitis. Allergol Int. 2017;66(3):392–7. https://doi.org/10.1016/j.alit.2017.02.015.CrossRefPubMed

148.

Kobori T, Hamasaki S, Kitaura A, Yamazaki Y, Nishinaka T, Niwa A, et al. Interleukin-18 amplifies macrophage polarization and morphological alteration, leading to excessive angiogenesis. Front Immunol. 2018;9:334. https://doi.org/10.3389/fimmu.2018.00334.CrossRefPubMedPubMedCentral

149.

Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–20. https://doi.org/10.1016/j.it.2016.01.004.CrossRefPubMedPubMedCentral

150.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood. 2015;126(13):1621–8. https://doi.org/10.1182/blood-2015-03-634691.CrossRefPubMedPubMedCentral

151.

Teng O, Ang CKE, Guan XL. Macrophage-bacteria interactions-a lipid-centric relationship. Front Immunol. 2017;8:1836. https://doi.org/10.3389/fimmu.2017.01836.CrossRefPubMedPubMedCentral

152.

Van Gorp H, Lamkanfi M. The emerging roles of inflammasome-dependent cytokines in cancer development. EMBO Rep. 2019;20(6). https://doi.org/10.15252/embr.201847575.

153.

Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O’Donnell JA, et al. NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity. 2012;37(6):1009–23. https://doi.org/10.1016/j.immuni.2012.08.027.CrossRefPubMedPubMedCentral

154.

Rodriguez-Cruz A, Vesin D, Ramon-Luing L, Zuniga J, Quesniaux VFJ, Ryffel B, et al. CD3(+) macrophages deliver proinflammatory cytokines by a CD3- and transmembrane TNF-dependent pathway and are increased at the BCG-infection site. Front Immunol. 2019;10:2550. https://doi.org/10.3389/fimmu.2019.02550.CrossRefPubMedPubMedCentral

155.

Kummer JA, Broekhuizen R, Everett H, Agostini L, Kuijk L, Martinon F, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem. 2007;55(5):443–52. https://doi.org/10.1369/jhc.6A7101.2006.CrossRefPubMed

156.

Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009;206(1):79–87. https://doi.org/10.1084/jem.20081667.CrossRefPubMedPubMedCentral

157.

Javanmard Khameneh H, Leong KWK, Mencarelli A, Vacca M, Mambwe B, Neo K, et al. The inflammasome adaptor ASC intrinsically limits CD4(+) T-cell proliferation to help maintain intestinal homeostasis. Front Immunol. 2019;10:1566. https://doi.org/10.3389/fimmu.2019.01566.CrossRefPubMedPubMedCentral

158.

Kolly L, Karababa M, Joosten LA, Narayan S, Salvi R, Petrilli V, et al. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J Immunol. 2009;183(6):4003–12. https://doi.org/10.4049/jimmunol.0802173.CrossRefPubMed

159.

Ippagunta SK, Brand DD, Luo J, Boyd KL, Calabrese C, Stienstra R, et al. Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. J Biol Chem. 2010;285(16):12454–62. https://doi.org/10.1074/jbc.M109.093252.CrossRefPubMedPubMedCentral

160.

Narayan S, Kolly L, So A, Busso N. Increased interleukin-10 production by ASC-deficient CD4+ T cells impairs bystander T-cell proliferation. Immunology. 2011;134(1):33–40. https://doi.org/10.1111/j.1365-2567.2011.03462.x.CrossRefPubMedPubMedCentral

161.

Stoecklein VM, Osuka A, Ishikawa S, Lederer MR, Wanke-Jellinek L, Lederer JA. Radiation exposure induces inflammasome pathway activation in immune cells. J Immunol. 2015;194(3):1178–89. https://doi.org/10.4049/jimmunol.1303051.CrossRefPubMed

162.

Bruchard M, Boidot R, Ghiringhelli F, Vegran F. Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice. Genom Data. 2015a;5:314–5. https://doi.org/10.1016/j.gdata.2015.06.031.CrossRefPubMedPubMedCentral

163.

Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, et al. The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol. 2015b;16(8):859–70. https://doi.org/10.1038/ni.3202.CrossRefPubMed

164.

Braga TT, Brandao WN, Azevedo H, Terra FF, Melo ACL, Pereira FV, et al. NLRP3 gain-of-function in CD4(+) T lymphocytes ameliorates experimental autoimmune encephalomyelitis. Clin Sci (Lond). 2019;133(17):1901–16. https://doi.org/10.1042/CS20190506.CrossRef

165.

Park SH, Ham S, Lee A, Moller A, Kim TS. NLRP3 negatively regulates Treg differentiation through Kpna2-mediated nuclear translocation. J Biol Chem. 2019;294(47):17951–61. https://doi.org/10.1074/jbc.RA119.010545.CrossRefPubMedPubMedCentral

166.

Eleftheriadis T, Pissas G, Antoniadi G, Makri P, Liakopoulos V, Stefanidis I. Urate crystals induce NLRP3 inflammasome-dependent IL-1beta secretion and proliferation in isolated primary human T-cells. Hippokratia. 2015;19(1):41–6.PubMedPubMedCentral

167.

Imanishi T, Ishihara C, Badr Mel S, Hashimoto-Tane A, Kimura Y, Kawai T, et al. Nucleic acid sensing by T cells initiates Th2 cell differentiation. Nat Commun. 2014;5:3566. https://doi.org/10.1038/ncomms4566.CrossRefPubMed

168.

Doitsh G, Greene WC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe. 2016;19(3):280–91. https://doi.org/10.1016/j.chom.2016.02.012.CrossRefPubMedPubMedCentral

169.

Martin BN, Wang C, Zhang CJ, Kang Z, Gulen MF, Zepp JA, et al. T cell-intrinsic ASC critically promotes T(H)17-mediated experimental autoimmune encephalomyelitis. Nat Immunol. 2016;17(5):583–92. https://doi.org/10.1038/ni.3389.CrossRefPubMedPubMedCentral

170.

Arbore G, West EE, Spolski R, Robertson AAB, Klos A, Rheinheimer C, et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science. 2016;352(6292):aad1210. https://doi.org/10.1126/science.aad1210.CrossRefPubMedPubMedCentral

171.

Gonzalez-Martin A, Sanchez-Lorenzo L. Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising? Cancer. 2019;125(Suppl 24):4616–22. https://doi.org/10.1002/cncr.32520.CrossRefPubMed

172.

Zhu J, Yang Y, Hu SG, Zhang QB, Yu J, Zhang YM. T-lymphocyte Kv1.3 channel activation triggers the NLRP3 inflammasome signaling pathway in hypertensive patients. Exp Ther Med. 2017;14(1):147–54. https://doi.org/10.3892/etm.2017.4490.CrossRefPubMedPubMedCentral

173.

Freeley S, Kemper C, Le Friec G. The “ins and outs” of complement-driven immune responses. Immunol Rev. 2016;274(1):16–32. https://doi.org/10.1111/imr.12472.CrossRefPubMedPubMedCentral

174.

Camell CD, Gunther P, Lee A, Goldberg EL, Spadaro O, Youm YH, et al. Aging induces an Nlrp3 inflammasome-dependent expansion of adipose B cells that impairs metabolic homeostasis. Cell Metab. 2019;30(6):1024–39 e6. https://doi.org/10.1016/j.cmet.2019.10.006.CrossRefPubMedPubMedCentral

175.

Ali MF, Dasari H, Van Keulen VP, Carmona EM. Canonical stimulation of the NLRP3 inflammasome by fungal antigens links innate and adaptive B-lymphocyte responses by modulating IL-1beta and IgM production. Front Immunol. 2017;8:1504. https://doi.org/10.3389/fimmu.2017.01504.CrossRefPubMedPubMedCentral

176.

Sudres M, Cire S, Vasseur V, Brault L, Da Rocha S, Boisgerault F, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther. 2012;20(8):1571–81. https://doi.org/10.1038/mt.2012.101.CrossRefPubMedPubMedCentral

177.

Patel D, Gaikwad S, Challagundla N, Nivsarkar M, Agrawal-Rajput R. Spleen tyrosine kinase inhibition ameliorates airway inflammation through modulation of NLRP3 inflammosome and Th17/Treg axis. Int Immunopharmacol. 2018;54:375–84. https://doi.org/10.1016/j.intimp.2017.11.026.CrossRefPubMed

178.

Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019b;10(2):128. https://doi.org/10.1038/s41419-019-1413-8.CrossRefPubMedPubMedCentral

179.

Caseley EA, Poulter JA, Rodrigues F. Immunome Project Consortium for Autoinflammatory D, McDermott MF. Inflammasome inhibition under physiological and pharmacological conditions. Genes Immun. 2020;21(4):211–23. https://doi.org/10.1038/s41435-020-0104-x.CrossRefPubMed

180.

Zhang X, Xu A, Lv J, Zhang Q, Ran Y, Wei C, et al. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. Eur J Med Chem. 2020;185:111822. https://doi.org/10.1016/j.ejmech.2019.111822.CrossRefPubMed

181.

Chui AJ, Okondo MC, Rao SD, Gai K, Griswold AR, Johnson DC, et al. N-terminal degradation activates the NLRP1B inflammasome. Science. 2019;364(6435):82–5. https://doi.org/10.1126/science.aau1208.CrossRefPubMedPubMedCentral

182.

Awad F, Assrawi E, Louvrier C, Jumeau C, Georgin-Lavialle S, Grateau G, et al. Inflammasome biology, molecular pathology and therapeutic implications. Pharmacol Ther. 2018;187:133–49. https://doi.org/10.1016/j.pharmthera.2018.02.011.CrossRefPubMed

183.

Shah D, Challagundla N, Dave V, Patidar A, Saha B, Nivsarkar M et al. nBerberine mediates tumor cell death by skewing tumor-associated immunosuppressive macrophages to inflammatory macrophages. 2021:153904.

184.

Tozser J, Benko S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1beta production. Mediat Inflamm. 2016;2016:5460302. https://doi.org/10.1155/2016/5460302.CrossRef

185.

Greaney AJ, Maier NK, Leppla SH, Moayeri M. Sulforaphane inhibits multiple inflammasomes through an Nrf2-independent mechanism. J Leukoc Biol. 2016;99(1):189–99. https://doi.org/10.1189/jlb.3A0415-155RR.CrossRefPubMed

186.

Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677–87. https://doi.org/10.1038/nm.3893.CrossRefPubMedPubMedCentral

187.

Yang G, Lee SJ, Kang HC, Cho YY, Lee HS, Zouboulis CC, et al. Repurposing auranofin, an anti-rheumatic gold compound, to treat acne vulgaris by targeting the NLRP3 inflammasome. Biomol Ther (Seoul). 2020;28(5):437–42. https://doi.org/10.4062/biomolther.2020.004.CrossRef

188.

Gaikwad S, Naveen C, Agrawal-Rajput R. Toll-like receptor-4 antagonism mediates benefits during neuroinflammation. Neural Regen Res. 2016;11(4):552–3. https://doi.org/10.4103/1673-5374.180732.CrossRefPubMedPubMedCentral

189.

Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J Immunol. 2009;182(11):7146–54. https://doi.org/10.4049/jimmunol.0803859.CrossRefPubMed

190.

Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, et al. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol. 2007;179(8):5592–603. https://doi.org/10.4049/jimmunol.179.8.5592.CrossRefPubMed

191.

Rub A, Dey R, Jadhav M, Kamat R, Chakkaramakkil S, Majumdar S, et al. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat Immunol. 2009;10(3):273–80. https://doi.org/10.1038/ni.1705.CrossRefPubMed

192.

Martin S, Saha B, Riley JL. The battle over mTOR: an emerging theatre in host-pathogen immunity. PLoS Pathog. 2012;8(9):e1002894. https://doi.org/10.1371/journal.ppat.1002894.CrossRefPubMedPubMedCentral

193.

Murugaiyan G, Saha B. IL-27 in tumor immunity and immunotherapy. Trends Mol Med. 2013;19(2):108–16. https://doi.org/10.1016/j.molmed.2012.12.002.CrossRefPubMed

194.

Andre S, Rodrigues V, Pemberton S, Laforge M, Fortier Y, Cordeiro-da-Silva A, et al. Antileishmanial drugs modulate IL-12 expression and inflammasome activation in primary human cells. J Immunol. 2020;204(7):1869–80. https://doi.org/10.4049/jimmunol.1900590.CrossRefPubMed

195.

Gregersen I, Sandanger O, Askevold ET, Sagen EL, Yang K, Holm S, et al. Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation. PLoS One. 2017;12(11):e0188387. https://doi.org/10.1371/journal.pone.0188387.CrossRefPubMedPubMedCentral

196.

Petes C, Odoardi N, Plater SM, Martin NL, Gee K. IL-27 amplifies cytokine responses to Gram-negative bacterial products and Salmonella typhimurium infection. Sci Rep. 2018;8(1):13704. https://doi.org/10.1038/s41598-018-32007-y.CrossRefPubMedPubMedCentral

197.

Iacano AJ, Lewis H, Hazen JE, Andro H, Smith JD, Gulshan K. Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1beta release. Sci Rep. 2019;9(1):11128. https://doi.org/10.1038/s41598-019-47610-w.CrossRefPubMedPubMedCentral

198.

Abdelaziz DH, Gavrilin MA, Akhter A, Caution K, Kotrange S, Khweek AA, Abdulrahman BA, Grandhi J, Hassan ZA, Marsh C, Wewers MD, Amer AO. Apoptosis-associated speck-like protein (ASC) controls Legionella pneumophila infection in human monocytes. J Biol Chem. 2011;286:3203–8.PubMedCrossRef

199.

Anand PK, Kanneganti TD. NLRP6 in infection and inflammation. Microbes Infect. 2013;15:661–8.PubMedCrossRef

200.

Borghini S, Tassi S, Chiesa S, Caroli F, Carta S, Caorsi R, Fiore M, Delfino L, Lasiglie D, Ferraris C, Traggiai E, Di Duca M, Santamaria G, D’Osualdo A, Tosca M, Martini A, Ceccherini I, Rubartelli A, Gattorno M. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum. 2011;63:830–9.PubMedPubMedCentralCrossRef

201.

Boxer MB, Shen M, Auld DS, Wells JA, Thomas CJ. A small molecule inhibitor of caspase 1. Bethesda (MD): Probe Reports from the NIH Molecular Libraries Program; 2010.

202.

Brodsky IE, Palm NW, Sadanand S, Ryndak MB, Sutterwala FS, Flavell RA, Bliska JB, Medzhitov R. A Yersinia effector protein promotes virulence by preventing inflammasome recognition of the type III secretion system. Cell Host Microbe. 2010;7:376–87.PubMedPubMedCentralCrossRef

203.

Chen H, Yang D, Han F, Tan J, Zhang L, Xiao J, Zhang Y, Liu Q. The bacterial T6SS Effector EvpP prevents NLRP3 inflammasome activation by inhibiting the Ca(2+)-dependent MAPK-Jnk pathway. Cell Host Microbe. 2017;21:47–58.PubMedCrossRef

204.

Correa RG, Khan PM, Askari N, Zhai D, Gerlic M, Brown B, Magnuson G, Spreafico R, Albani S, Sergienko E, Diaz PW, Roth GP, Reed JC. Discovery and characterization of 2-aminobenzimidazole derivatives as selective NOD1 inhibitors. Chem Biol. 2011;18:825–32.PubMedPubMedCentralCrossRef

205.

da Cruz HLA, Cavalcanti CAJ, de Azevedo Silva J, de Lima CAD, Fragoso TS, Barbosa AD, Dantas AT, de Ataide Mariz H, Duarte A, Pontillo A, Crovella S, Sandrin-Garcia P. Differential expression of the inflammasome complex genes in systemic lupus erythematosus. Immunogenetics. 2020;72:217–24.PubMedCrossRef

206.

Deng W, Yang Z, Yue H, Ou Y, Hu W, Sun P. Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. Free Radic Biol Med. 2020;152:8–17.PubMedCrossRef

207.

Di Micco A, Frera G, Lugrin J, Jamilloux Y, Hsu ET, Tardivel A, De Gassart A, Zaffalon L, Bujisic B, Siegert S, Quadroni M, Broz P, Henry T, Hrycyna CA, Martinon F. AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity. Proc Natl Acad Sci U S A. 2016;113:E4671–80.PubMedPubMedCentralCrossRef

208.

Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002;99:11908–13.PubMedPubMedCentralCrossRef

209.

Docherty LE, Rezwan FI, Poole RL, Turner CL, Kivuva E, Maher ER, Smithson SF, Hamilton-Shield JP, Patalan M, Gizewska M, Peregud-Pogorzelski J, Beygo J, Buiting K, Horsthemke B, Soellner L, Begemann M, Eggermann T, Baple E, Mansour S, et al. Mutations in NLRP5 are associated with reproductive wastage and multilocus imprinting disorders in humans. Nat Commun. 2015;6:8086.PubMedCrossRef

210.

Dotson RJ, Rabadi SM, Westcott EL, Bradley S, Catlett SV, Banik S, Harton JA, Bakshi CS, Malik M. Repression of inflammasome by Francisella tularensis during early stages of infection. J Biol Chem. 2013;288:23844–57.PubMedPubMedCentralCrossRef

211.

Ellwanger K, Becker E, Kienes I, Sowa A, Postma Y, Cardona Gloria Y, Weber ANR, Kufer TA. The NLR family pyrin domain-containing 11 protein contributes to the regulation of inflammatory signaling. J Biol Chem. 2018;293:2701–10.PubMedPubMedCentralCrossRef

212.

Fernandes R, Tsuda C, Perumalsamy AL, Naranian T, Chong J, Acton BM, Tong ZB, Nelson LM, Jurisicova A. NLRP5 mediates mitochondrial function in mouse oocytes and embryos. Biol Reprod. 2012;86(138):131–10.

213.

Galle M, Schotte P, Haegman M, Wullaert A, Yang HJ, Jin S, Beyaert R. The Pseudomonas aeruginosa Type III secretion system plays a dual role in the regulation of caspase-1 mediated IL-1beta maturation. J Cell Mol Med. 2008;12:1767–76.PubMedCrossRef

214.

Ge J, Gong YN, Xu Y, Shao F. Preventing bacterial DNA release and absent in melanoma 2 inflammasome activation by a Legionella effector functioning in membrane trafficking. Proc Natl Acad Sci U S A. 2012;109:6193–8.PubMedPubMedCentralCrossRef

215.

Gil-Varea E, Urcelay E, Vilarino-Guell C, Costa C, Midaglia L, Matesanz F, Rodriguez-Antiguedad A, Oksenberg J, Espino-Paisan L, Dessa Sadovnick A, Saiz A, Villar LM, Garcia-Merino JA, Ramio-Torrenta L, Trivino JC, Quintana E, Robles R, Sanchez-Lopez A, Arroyo R, et al. Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. J Neuroinflammation. 2018;15:265.PubMedPubMedCentralCrossRef

216.

Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 2003;24:652–8.PubMedCrossRef

217.

Gregory SM, Davis BK, West JA, Taxman DJ, Matsuzawa S, Reed JC, Ting JP, Damania B. Discovery of a viral NLR homolog that inhibits the inflammasome. Science. 2011;331:330–4.PubMedPubMedCentralCrossRef

218.

Guo Q, Wu Y, Hou Y, Liu Y, Liu T, Zhang H, Fan C, Guan H, Li Y, Shan Z, Teng W. Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis. Front Immunol. 2018;9:1197.PubMedPubMedCentralCrossRef

219.

Harding KE, Robertson NP. New rare genetic variants in multiple sclerosis. J Neurol. 2019;266:278–80.PubMedCrossRef

220.

He H, Jiang H, Chen Y, Ye J, Wang A, Wang C, Liu Q, Liang G, Deng X, Jiang W, Zhou R. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9:2550.PubMedPubMedCentralCrossRef

221.

He Y, Varadarajan S, Munoz-Planillo R, Burberry A, Nakamura Y, Nunez G. 3,4-methylenedioxy-beta-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014;289:1142–50.PubMedCrossRef

222.

Herlin T, Jorgensen SE, Host C, Mitchell PS, Christensen MH, Laustsen M, Larsen DA, Schmidt FI, Christiansen M, Mogensen TH. Autoinflammatory disease with corneal and mucosal dyskeratosis caused by a novel NLRP1 variant. Rheumatology (Oxford). 2019;59.9:2334–2339. https://doi.org/10.1093/rheumatology/kez612

223.

Higa N, Toma C, Koizumi Y, Nakasone N, Nohara T, Masumoto J, Kodama T, Iida T, Suzuki T. Vibrio parahaemolyticus effector proteins suppress inflammasome activation by interfering with host autophagy signaling. PLoS Pathog. 2013;9:e1003142.PubMedPubMedCentralCrossRef

224.

Hisahara S, Yuan J, Momoi T, Okano H, Miura M. Caspase-11 mediates oligodendrocyte cell death and pathogenesis of autoimmune-mediated demyelination. J Exp Med. 2001;193:111–22.PubMedPubMedCentralCrossRef

225.

Huang JY, Su M, Lin SH, Kuo PL. A genetic association study of NLRP2 and NLRP7 genes in idiopathic recurrent miscarriage. Hum Reprod. 2013;28:1127–34.PubMedCrossRef

226.

Jakka P, Namani S, Murugan S, Rai N, Radhakrishnan G. The Brucella effector protein TcpB induces degradation of inflammatory caspases and thereby subverts non-canonical inflammasome activation in macrophages. J Biol Chem. 2017;292:20613–27.PubMedPubMedCentralCrossRef

227.

Jakopin Z. Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway. J Med Chem. 2014;57:6897–918.PubMedCrossRef

228.

Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q, Jin T, Jiang W, Deng X, Zhou R. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214:3219–38.PubMedPubMedCentralCrossRef

229.

Johnston JB, Barrett JW, Nazarian SH, Goodwin M, Ricciuto D, Wang G, McFadden G. A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity. 2005;23:587–98.PubMedCrossRef

230.

Juliana C, Fernandes-Alnemri T, Wu J, Datta P, Solorzano L, Yu JW, Meng R, Quong AA, Latz E, Scott CP, Alnemri ES. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285:9792–802.PubMedPubMedCentralCrossRef

231.

Kaur G, Bagam P, Pinkston R, Singh DP, Batra S. Cigarette smoke-induced inflammation: NLRP10-mediated mechanisms. Toxicology. 2018;398-399:52–67.PubMedCrossRef

232.

Kavathas PB, Boeras CM, Mulla MJ, Abrahams VM. Nod1, but not the ASC inflammasome, contributes to induction of IL-1beta secretion in human trophoblasts after sensing of Chlamydia trachomatis. Mucosal Immunol. 2013;6:235–43.PubMedCrossRef

233.

Kobayashi T, Ogawa M, Sanada T, Mimuro H, Kim M, Ashida H, Akakura R, Yoshida M, Kawalec M, Reichhart JM, Mizushima T, Sasakawa C. The Shigella OspC3 effector inhibits caspase-4, antagonizes inflammatory cell death, and promotes epithelial infection. Cell Host Microbe. 2013;13:570–83.PubMedCrossRef

234.

Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, Gakidis MA, Rao A, Sekine T, Ikegami F, Yuan C, Yuan J. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004;11:123–30.PubMedCrossRef

235.

Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015;1852:1114–23.PubMedCrossRef

236.

Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, Lee WP, Hoffman HM, Dixit VM. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187:61–70.PubMedPubMedCentralCrossRef

237.

LaRock CN, Cookson BT. The Yersinia virulence effector YopM binds caspase-1 to arrest inflammasome assembly and processing. Cell Host Microbe. 2012;12:799–805.PubMedPubMedCentralCrossRef

238.

Le Bourhis L, Benko S, Girardin SE. Nod1 and Nod2 in innate immunity and human inflammatory disorders. Biochem Soc Trans. 2007;35:1479–84.PubMedCrossRef

239.

Li J, Kong L, Gao Y, Wu C, Xu T. Characterization of NLR-A subfamily members in miiuy croaker and comparative genomics revealed NLRX1 underwent duplication and lose in actinopterygii. Fish Shellfish Immunol. 2015;47:397–406.PubMedCrossRef

240.

Liu W, Guo W, Wu J, Luo Q, Tao F, Gu Y, Shen Y, Li J, Tan R, Xu Q, Sun Y. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013;85:1504–12.PubMedCrossRef

241.

Liu Y, Tang ZZ, Zhang YM, Kong L, Xiao WF, Ma TF, Liu YW. Thrombin/PAR-1 activation induces endothelial damages via NLRP1 inflammasome in gestational diabetes. Biochem Pharmacol. 2020;175:113849.PubMedCrossRef

242.

Lukens JR, Gurung P, Shaw PJ, Barr MJ, Zaki MH, Brown SA, Vogel P, Chi H, Kanneganti TD. The NLRP12 sensor negatively regulates autoinflammatory disease by modulating interleukin-4 production in T cells. Immunity. 2015;42:654–64.PubMedPubMedCentralCrossRef

243.

Master SS, Rampini SK, Davis AS, Keller C, Ehlers S, Springer B, Timmins GS, Sander P, Deretic V. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe. 2008;3:224–32.PubMedPubMedCentralCrossRef

244.

Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166:1–15.PubMedPubMedCentralCrossRef

245.

Meyer E, Lim D, Pasha S, Tee LJ, Rahman F, Yates JR, Woods CG, Reik W, Maher ER. Germline mutation in NLRP2 (NALP2) in a familial imprinting disorder (Beckwith-Wiedemann Syndrome). PLoS Genet. 2009;5:e1000423.PubMedPubMedCentralCrossRef

246.

Miao EA, Alpuche-Aranda CM, Dors M, Clark AE, Bader MW, Miller SI, Aderem A. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol. 2006;7:569–75.PubMedCrossRef

247.

Muller DN, Heissmeyer V, Dechend R, Hampich F, Park JK, Fiebeler A, Shagdarsuren E, Theuer J, Elger M, Pilz B, Breu V, Schroer K, Ganten D, Dietz R, Haller H, Scheidereit C, Luft FC. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J. 2001;15:1822–4.PubMedCrossRef

248.

Ohno S, Kinoshita T, Ohno Y, Minamoto T, Suzuki N, Inoue M, Suda T. Expression of NLRP7 (PYPAF3, NALP7) protein in endometrial cancer tissues. Anticancer Res. 2008;28:2493–7.PubMed

249.

Ozel I, Akkaya I, Oylumlu E, Uzel G, Ciraci C. Adenosine-induced NLRP11 in B lymphoblasts suppresses human CD4(+) T helper cell responses. J Immunol Res. 2020;2020:1421795.PubMedPubMedCentralCrossRef

250.

Panchanathan R, Duan X, Shen H, Rathinam VA, Erickson LD, Fitzgerald KA, Choubey D. Aim2 deficiency stimulates the expression of IFN-inducible Ifi202, a lupus susceptibility murine gene within the Nba2 autoimmune susceptibility locus. J Immunol. 2010;185:7385–93.PubMedCrossRef

251.

Perregaux DG, McNiff P, Laliberte R, Hawryluk N, Peurano H, Stam E, Eggler J, Griffiths R, Dombroski MA, Gabel CA. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther. 2001;299:187–97.PubMed

252.

Rabes A, Suttorp N, Opitz B. Inflammasomes in pneumococcal infection: innate immune sensing and bacterial evasion strategies. Curr Top Microbiol Immunol. 2016;397:215–27.PubMed

253.

Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS, Pickup DJ. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell. 1992;69:597–604.PubMedCrossRef

254.

Reyes Ruiz VM, Ramirez J, Naseer N, Palacio NM, Siddarthan IJ, Yan BM, Boyer MA, Pensinger DA, Sauer JD, Shin S. Broad detection of bacterial type III secretion system and flagellin proteins by the human NAIP/NLRC4 inflammasome. Proc Natl Acad Sci U S A. 2017;114:13242–7.PubMedPubMedCentralCrossRef

255.

Romberg N, Vogel TP, Canna SW. NLRC4 inflammasomopathies. Curr Opin Allergy Clin Immunol. 2017;17:398–404.PubMedPubMedCentralCrossRef

256.

Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The pyrin inflammasome in health and disease. Front Immunol. 2019;10:1745.PubMedPubMedCentralCrossRef

257.

Schotte P, Denecker G, Van Den Broeke A, Vandenabeele P, Cornelis GR, Beyaert R. Targeting Rac1 by the Yersinia effector protein YopE inhibits caspase-1-mediated maturation and release of interleukin-1beta. J Biol Chem. 2004;279:25134–42.PubMedCrossRef

258.

Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, Kruger S, Vogel T, Knaebel HP, Ruschoff J, Hahn SA, Knebel-Doeberitz MV, Moeslein G, Meltzer SJ, Schackert HK, Tympner C, Mangold E, Schmiegel W, German HC. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology. 2005;128:590–9.PubMedCrossRef

259.

Shi Y, Wang H, Zheng M, Xu W, Yang Y, Shi F. Ginsenoside Rg3 suppresses the NLRP3 inflammasome activation through inhibition of its assembly. FASEB J. 2020;34:208–21.PubMedCrossRef

260.

Stasakova J, Ferko B, Kittel C, Sereinig S, Romanova J, Katinger H, Egorov A. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol. 2005;86:185–95.PubMedCrossRef

261.

Stehlik C, Dorfleutner A. COPs and POPs: modulators of inflammasome activity. J Immunol. 2007;179:7993–8.PubMedCrossRef

262.

Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 1993;75:135–46.PubMedCrossRef

263.

Sutterwala FS, Mijares LA, Li L, Ogura Y, Kazmierczak BI, Flavell RA. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med. 2007;204:3235–45.PubMedPubMedCentralCrossRef

264.

Taxman DJ, Huang MT, Ting JP. Inflammasome inhibition as a pathogenic stealth mechanism. Cell Host Microbe. 2010;8:7–11.PubMedPubMedCentralCrossRef

265.

Uh ST, Park JS, Koo SM, Kim YK, Kim KU, Kim MA, Shin SW, Son JH, Park HW, Shin HD, Park CS, Chang HS. Association of genetic variants of NLRP4 with exacerbation of asthma: the effect of smoking. DNA Cell Biol. 2019;38:76–84.PubMedCrossRef

266.

Ulker V, Gurkan H, Tozkir H, Karaman V, Ozgur H, Numanoglu C, Gedikbasi A, Akbayir O, Uyguner ZO. Novel NLRP7 mutations in familial recurrent hydatidiform mole: are NLRP7 mutations a risk for recurrent reproductive wastage? Eur J Obstet Gynecol Reprod Biol. 2013;170:188–92.PubMedCrossRef

267.

Velasco E, Valero C, Valero A, Moreno F, Hernandez-Chico C. Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of cBCD541 and SMA phenotype. Hum Mol Genet. 1996;5:257–63.PubMedCrossRef

268.

Wang LY, Sun XJ, Chen M, Zhao MH. The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Transl Med. 2019c;17:197.PubMedPubMedCentralCrossRef

269.

Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, D'Agostino D, Planavsky N, Lupfer C, Kanneganti TD, Kang S, Horvath TL, Fahmy TM, Crawford PA, Biragyn A, Alnemri E, Dixit VD. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263–9.PubMedPubMedCentralCrossRef

270.

Yu SX, Du CT, Chen W, Lei QQ, Li N, Qi S, Zhang XJ, Hu GQ, Deng XM, Han WY, Yang YJ. Genipin inhibits NLRP3 and NLRC4 inflammasome activation via autophagy suppression. Sci Rep. 2015;5:17935.PubMedPubMedCentralCrossRef

271.

Zahid A, Li B, Kombe AJK, Jin T, Tao J. Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 2019;10:2538.PubMedPubMedCentralCrossRef

272.

Zhao Y, Shao F. The NAIP-NLRC4 inflammasome in innate immune detection of bacterial flagellin and type III secretion apparatus. Immunol Rev. 2015;265:85–102.PubMedCrossRef

273.

Zhou X, Gordon SA, Kim YM, Hoffman RA, Chen Y, Zhang XR, Simmons RL, Ford HR. Nitric oxide induces thymocyte apoptosis via a caspase-1-dependent mechanism. J Immunol. 2000;165:1252–8.PubMedCrossRef

274.

Zorman J, Susjan P, Hafner-Bratkovic I. Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1. PLoS One. 2016;11:e0159826.PubMedPubMedCentralCrossRef

275.

Zupin L, Navarra CO, Robino A, Bevilacqua L, Di Lenarda R, Gasparini P, Crovella S. NLRC5 polymorphism is associated with susceptibility to chronic periodontitis. Immunobiology. 2017;222:704–8.PubMedCrossRef

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Insights into inflammasome regulation: cellular, molecular, and pathogenic control of inflammasome activation

Abstract

Graphical abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing–remitting multiple sclerosis

Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels

High mobility group box 1 (HMGB1) inhibition attenuates lipopolysaccharide-induced cognitive dysfunction and sickness-like behavior in mice

In-utero exposure to immunosuppressive medications resulting in abnormal newborn screening for severe combined immunodeficiency: a case series on natural history and management